Deep learning-based interpretable prediction of recurrence of diffuse large B-cell lymphoma
Abstract Background The heterogeneous and aggressive nature of diffuse large B-cell lymphoma (DLBCL) presents significant treatment challenges as up to 50% of patients experience recurrence of disease after chemotherapy. Upfront detection of recurring patients could offer alternative treatments. Dee...
Saved in:
| Main Authors: | Hussein Naji, Paul Hahn, Juan I. Pisula, Stefano Ugliano, Adrian Simon, Reinhard Büttner, Katarzyna Bozek |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | BJC Reports |
| Online Access: | https://doi.org/10.1038/s44276-025-00147-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenalidomide in Diffuse Large B-Cell Lymphomas
by: Annalisa Chiappella, et al.
Published: (2012-01-01) -
Lenalidomide in Diffuse Large B-Cell Lymphoma
by: Catherine Thieblemont, et al.
Published: (2012-01-01) -
Personalized medicine in diffuse large B-cell lymphoma
by: Prashant Mehta, et al.
Published: (2019-01-01) -
Diffuse large B-cell lymphoma misdiagnosed as cellulitis
by: Tamotsu Kuribayashi, et al.
Published: (2025-04-01) -
Renal Involvement in Diffuse Large B-cell Lymphoma
by: Shashikant Saini, et al.
Published: (2024-10-01)